financetom
Business
financetom
/
Business
/
Why CureVac (CVAC) Stock Is Rising
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why CureVac (CVAC) Stock Is Rising
Jan 6, 2025 8:42 AM

Shares of CureVac BV are trading higher by 13.5% to $4.10 during Monday’s session following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

The surge in healthcare visits, driven by higher cases of seasonal influenza, COVID-19 and RSV, has renewed interest in vaccine and therapeutic manufacturers during Monday’s trading session.

CureVac ( CVAC ), a biotechnology company specializing in mRNA technology, is seen as a key player in developing next-generation vaccines. The company is advancing its mRNA platform to address not only COVID-19 but also other respiratory viruses like RSV and influenza.

CureVac's ( CVAC ) pipeline includes partnerships and clinical trials targeting these illnesses, potentially making the company well-positioned to benefit from heightened demand for respiratory virus treatments.

Read Also: Uber CFO Says Stock Undervalued, Initiates $1.5 Billion Accelerated Stock Buyback

How To Buy CVAC Stock

By now you're likely curious about how to participate in the market for CureVac ( CVAC ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

In the case of CureVac ( CVAC ), which is trading at $4.07 as of publishing time, $100 would buy you 24.57 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, CVAC has a 52-week high of $5.28 and a 52-week low of $2.22.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Jun 10, 2024
June 10 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1945 GMT on Monday: ** Former media executive Edgar Bronfman Jr., backed by private equity firm Bain Capital, has expressed interest in buying Paramount's controlling shareholder National Amusements, a source familiar with the matter said. ** Spanish holding firm Criteria said it had not reached an...
Bitcoin Mining Stock Hive Digital Is Rising Monday: What's Going On?
Bitcoin Mining Stock Hive Digital Is Rising Monday: What's Going On?
Jun 10, 2024
HIVE Digital Technologies Ltd ( HIVE ) shares are trading higher. The company on Monday announced Bitcoin (CRYPTO: BTC) production numbers for May. What Happened: In May, Hive Digital ( HIVE ) said it mined 119 bitcoin, bringing its total bitcoin holdings up to 2,451. The company maintained average mining capacity of 4.9 EH/s during the month and ended the...
JPMorgan Chase Unusual Options Activity For June 10
JPMorgan Chase Unusual Options Activity For June 10
Jun 10, 2024
Deep-pocketed investors have adopted a bullish approach towards JPMorgan Chase ( JPM ) , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JPM usually suggests something big is about to happen. We gleaned this information...
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
Jun 10, 2024
04:06 PM EDT, 06/10/2024 (MT Newswires) -- Leonard S Schleifer, Director, Board Co-Chair, President & CEO, on June 06, 2024, sold 787 shares in Regeneron Pharmaceuticals ( REGN ) for $798,821. Following the Form 4 filing with the SEC, Schleifer has control over a total of 694,559 shares of the company, with 466,877 shares held directly and 227,682 controlled indirectly....
Copyright 2023-2026 - www.financetom.com All Rights Reserved